With 3 approved epigenetic drug classes and many more under clinical investigation, epigenetic targets are gaining traction. Here, we take survey of developments and hurdles in targeting the cancer epigenome. Thank you @NatureCancer for the opportunity.

New publication by #teamneuroblastoma in the @KStegmaier_DFCI lab in collaboration with the Dent lab at MD Anderson. Happy to have helped bring this one over the finish line after the work done by @clarebear1060 and @FormanAllie.

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

Today marks the close of the postdoc chapter. I am fortunate to have called the @KStegmaier_DFCI home for the last 5 years. It was a privilege to work alongside so many amazing and talented scientists throughout this journey. Thank you for all the good memories!

We'll be opening lab doors in May and are recruiting a research technician with a start in May or June. If you are interested in studying pediatric cancer please reach out or apply. @Purdue_MCMP @PUCancerInst @purduepharmacy.

Amazing news to hear on a football Saturday. Thank you Trent family for your support and advocacy. Very excited to help make pediatric cancer research a priority at Purdue.

RT @Purdue_MCMP: @Purdue_MCMP is hiring for Faculty Positions in Translational Neuroscience and Chemical Biology ht….

@Purdue_MCMP @purduepharmacy @PUCancerInst @LifeAtPurdue Thank you (as always!) to all of the amazing mentors, supporters, collaborators, funders, and individuals who have made this dream a reality. More information to come in the winter!.

I'm thrilled to share that I’ll be joining @Purdue_MCMP @purduepharmacy @PUCancerInst @LifeAtPurdue as an assistant professor starting summer 2024. We’ll be studying the intersection of epigenetics, cell state, and therapeutics in pediatric solid tumors.

Also a big thank you to my mentors over the years @KStegmaier_DFCI @alvarezlabhutch @Majzner_Lab and twitterless Boyd Rorabaugh. This wouldn't have been possible without your support.

Very thankful to receive a K99/R00 to continue studying epigenetic mechanisms regulating therapy response in neuroblastoma. A big thank you to @theNCI who has supported me through all steps of my training.

RT @MartaBarisa: 🌟Long-awaited proof-of-concept that CAR-T can eradicate solid tumours - and in immune cold paediatric tumours. Brava, Loca….

RT @Majzner_Lab: Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student….

RT @KStegmaier_DFCI: Check out two new publications on Ewing sarcoma and ETV6 in @NatureCellBio from our lab and @ChrisVakoc. Excited to s….

RT @BlaineyLab: Online today in @CellCellPress! Our fab collaboration with @iaincheeseman lab: image-based screen 5K+ essential genes to bu….

RT @ADurbinLab: Holy cow! Open call for a Researcher position (MSc or PhD, no post-doc experience needed). This will person will be a part….

RT @ranigeorgelab: Our work led by @senspeaks and @sanjuktadas25,.connecting tumor cell lineage to immunogenic phenotypes in neuroblastoma,….

A huge thank you to everybody who contributed and supported the study. Especially Jon who led the bulk of assembling and writing the manuscript. Also Bernhard who completed all of the studies in DIPG.

Excited to share our newest story with @JCI_insight. A joint collaboration between William Hahn, @FilbinMariella , and @KStegmaier_DFCI labs. VRK1 is a synthetic lethal target in neural-lineage cancers expressing low VRK2.

EZH2 inhibitor therapy was not associated with increased GD2 expression in healthy neural tissue, suggesting it can be advanced into clinical studies to prevent GD2 downregulation or enhance anti-GD2 therapy response.

ST8SIA1 expression is regulated by EZH2-dependent methylation of H3K27me3. Treatment of GD2-low cell lines with EZH2 inhibitors rewired cells into an adrenergic-like state, re-expresses ST8SIA1, and restores sensitivity to anti-GD2 therapy in vitro and in vivo.